Gurugram: Central diagnosis announced its exclusive partnership with Digistain. The collaboration aims to bring the breast cancer risk profiling technologyDigistain, to India, Nepal, Bhutan and Bangladesh.
Digistain is a digital solution for cancer classification and forecast, approved by the Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom. Offers a fast, affordable and AI-enabled solution to predict the probability of breast cancer recurrence after surgery. This technology is designed to prevent breast cancer patients from undergoing unnecessary chemotherapy.
It has been developed with input from over 1,500 oncologists and has been successfully trialled at leading cancer centers including Nottingham University NHS Trust, the National Institute for Health Research (NIHR) and Cancer Research UK.
The digital solution has been thoroughly vetted by the National Health Service (NHS), affirming its commitment to meeting the highest standards of medical safety and effectiveness. This NHS endorsement not only underlines the reliability of Digistain technologies but also ensures they meet the rigorous demands of healthcare professionals and patients.
The introduction of the digital solution in India and its neighboring states through this partnership is expected to revolutionize the health industryThe approach to breast cancer treatment. With its AI-based technology, Digistain has the potential to improve diagnostic accuracy, reduce treatment costs, and ultimately save lives. This collaboration aligns with India’s broader healthcare goals of leveraging innovative solutions to address pressing healthcare challenges and improve patient care across the country.
“This partnership represents an important step forward in the fight against breast cancer by providing a faster, more accurate and cost-effective approach to cancer prognosis and treatment,” said Dinesh Chauhan, CEO of Core Diagnostics.
We have to continually be jumping off cliffs and developing our wings on the way down.’ -Kurt Vonnegut
